PT  - JOURNAL ARTICLE
AU  - Kertes, Jennifer
AU  - Baruch Gez, Sharon
AU  - Saciuk, Yaki
AU  - Supino-Rosin, Lia
AU  - Shamir Stein, Naama
AU  - Mizrahi-Reuveni, Miri
AU  - Ekka Zohar, Anat
TI  - Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: findings from a large Israeli HMO
AID  - 10.1101/2021.09.01.21262957
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.01.21262957
4099  - http://medrxiv.org/content/early/2021/09/07/2021.09.01.21262957.short
4100  - http://medrxiv.org/content/early/2021/09/07/2021.09.01.21262957.full
AB  - Israel is currently experiencing a new wave of CoVid-19 infection, six months after implementing a national vaccination campaign. We carried out three discrete analyses using data from a large Israeli HMO to determine whether IgG levels of those fully vaccinated drop over time, the relationship between IgG titer and subsequent PCR-confirmed infection, and compare PCR-confirmed infection rates by period of vaccination. We found that mean IgG antibody levels steadily decreased over the six-month period in the total tested population, and in all age groups. An inverse relationship was found between IgG titer and subsequent CoVid-19 infection (PCR-positive). Those participants vaccinated in the first two months of the campaign were more likely to become infected than those subsequently vaccinated. The 60+ vaccinated had lower initial IgG levels, and were at greater risk of infection. The findings support the decision to add a booster vaccine for those aged 60 and over.Article Summary Line The BNT162b2 vaccine was found to be less effective in protecting against Covid-19 infection after six months, and vaccination with a third dose is indicated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Maccabi Helsinki Committee (#0178-20-MHS), with informed consent waived, as all data extracted from the database were anomized and aggregated.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable from corresponding author upon reasonable request